SCA
RGNX icon

Secor Capital Advisors’s Regenxbio RGNX Stock Holding History

Secor Capital Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-54,350
Closed -$1.62M – 616
2018
Q1 		$1.62M Buy
54,350
+37,345
+220% +$1.09M 0.13% 238
2017
Q4 		$565K Sell
17,005
-14,586
-46% -$439K 0.02% 348
2017
Q3 		$1.04M Buy
+31,591
New +$711K 0.1% 268

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WM
WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Secor Capital Advisors's RGNX Position: Q2 2018 in Review

Secor Capital Advisors sold out of Regenxbio (RGNX) in Q2 2018, closing a stake of 54,350 shares — an estimated $1.62M sold.

Secor Capital Advisors first reported a position in RGNX in Q3 2017 and held it in 3 quarters. The position peaked at $1.62M in Q1 2018. 177 funds tracked by Wall St. Rank hold RGNX as of Q2 2018.

  • Secor Capital Advisors reported no remaining Regenxbio position as of Q2 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 54,350 Regenxbio shares in Q2 2018, an estimated $1.62M.
  • Secor Capital Advisors first reported a position in Regenxbio in Q3 2017 and held it in 3 quarters.
  • Secor Capital Advisors's Regenxbio position peaked at $1.62M in Q1 2018.
  • 177 funds tracked by Wall St. Rank held Regenxbio as of Q2 2018.

Based on Secor Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.